MedPath

Altena, Renske

🇸🇪Sweden
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

Phase 2
Not yet recruiting
Conditions
Breast Cancer Stage IV
HER2-low Breast Cancer
Molecular Imaging
First Posted Date
2025-02-17
Last Posted Date
2025-02-17
Lead Sponsor
Renske Altena
Target Recruit Count
70
Registration Number
NCT06830382

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

First Posted Date
2019-03-28
Last Posted Date
2021-09-23
Lead Sponsor
Renske Altena
Target Recruit Count
6
Registration Number
NCT03894007
Locations
🇸🇪

Sahlgrenska universitetssjukhuset, Göteborg, Sweden

🇸🇪

Skånes universitetssjukhus, Malmö, Sweden

🇸🇪

Karolinska universitetssjukhuset, Stockholm, Sweden

and more 5 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.